
    
      A multi-center, observational, prospective, cohort study to assess the safety and
      effectiveness of biosimilar Infliximab (Remsima®) in patients with rheumatoid arthritis in
      Jordan. Biologic naïve patients will receive Remsima® in accordance with standard medical
      care and the approved label and will be followed over a period of 34 weeks (8.5 months).
      Outcomes including occurrence of adverse events (AEs), mean changes in disease activity and
      health assessment in each cohort will be measured and compared
    
  